BSECompany Update13h ago · 25 Sept 2026, 10:31 pm
Kindly refer the attachment
Sanofi India Ltd · 500674
✦ AI SummaryRegulatory
Sanofi India Ltd received a Show Cause Notice from GST Authorities alleging excess claim of Input Tax Credit for FY 2022-23, with a proposed tax liability of Rs.14,43,01,828 along with interest of Rs.9,30,74,679. The company is in the process of responding to the notice and does not envisage any adverse impact on its financials, operations, or other activities.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk8/10
Balance Sheet Risk4/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sanofi India Ltd - 500674 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Attachments (1)
📄pdf
Download →
031ef222-25d6-4f4f-8012-08bd834f3db2.pdf
View document text
25th September 2026
The Secretary The Secretary
BSE Limited The National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G,
Dalal Street Bandra-Kurla Complex, Bandra (E)
Mumbai 400 001 Mumbai 400 051
Scrip Code: 500674 Symbol: SANOFI
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 – Receipt of Show Cause Notice
from GST Authorities
Dear Sir/ Madam,
In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (“the Listing Regulations”), this is to inform you
that the Company, is in receipt of a Show Cause Notice dated 25th September 2026,
issued under Section 73 of the Karnataka Goods and Services Tax Act,2017. The
Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru, alleged that the Company
has availed excess of Input Tax Credit for the period April 2022 to March 2023. The
GST official has proposed to determine Tax liability of Rs.14,43,01,828 along with
interest of Rs.9,30,74,679 aggregating to Rs. 23,73,76,507.
The Company is in the process of responding to the notice after receiving the relevant
facts basis thereon above demand has been determined.
The information required in terms of Regulation 30 read with Clause 8 of Para B of
Part A of Schedule III of the Listing Regulations and SEBI Master Circular No.
HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 and Industry
Standards on Regulation 30 of the Listing Regulations, are enclosed as ‘Annexure-I’.
This information is also made available on the website of the Company.
We request you to kindly take the above on record.
Thanking you,
Yours faithfully,
For Sanofi India Limited
Haresh Vala
Company Secretary and Compliance Officer
Membership No.: A18246
Encl: a/a
Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 – India Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939
Corporate Identity Number: L24239MH1956PLC009794 Website: www.sanofiindialtd.com | www.sanofi.in Email: igrc.sil@sanofi.com
Annexure – I
Information as required under Regulation 30 read with Clause 8 of
Para B of Part A of Schedule III of the Listing Regulations
Sr. Particulars Description
1. Type of communication The Company received Show Cause Notice dated
received 25th September 2026 issued under Section 73 of
the Karnataka Goods and Services Tax Act,2017
in relation to alleged excess claim of Input Tax
Credit for FY 2022-23.
2. Date of receipt of 25th September 2026
communication
3. Name of the Authority Commercial Tax Officer (Audit)-6.1, DGSTO-6,
Bengaluru
4. Brief details of dispute / Show Cause Notice alleging tax demand of
litigation viz. name(s) of Rs.14,43,01,828 along with interest of
the opposing party, court/ Rs.9,30,74,679 in relation to alleged excess claim
tribunal/agency where of Input Tax Credit for FY 2022-23.
litigation is filed, brief
details of
dispute/litigation;
5. Expected financial The Company, in consultation with its consultant
implications, if any, due to / tax advisors, is examining the Show Cause
compensation, penalty Notice as received and shall take appropriate
etc.; steps including submission of reply within the
prescribed time period. The Company does not
envisage any adverse impact on the financials,
operations or other activities of the Company
arising from this Show Cause Notice.
6. Quantum of claims, if any; As described in Sr. No. 4 above
Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 – India Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939
Corporate Identity Number: L24239MH1956PLC009794 Website: www.sanofiindialtd.com | www.sanofi.in Email: igrc.sil@sanofi.com